Esophageal squamous cell carcinoma (ESCC) has a multifactorial etiology involving environmental and/or genetic factors. End-binding protein 1 (EB1), which was cloned as an interacting partner of the adenomatous polyposis coli (APC) tumor suppressor protein, was previously found overexpressed in ESCC. However, the precise role of EB1 in the development of this malignancy has not yet been elucidated. In this study, we analysed freshly resected ESCC specimens and demonstrated that EB1 was overexpressed in approximately 63% of tumor samples compared to matched normal tissue. We report that overexpression of EB1 in the ESCC line EC9706 significantly promotes cell growth, whereas suppression of EB1 protein level by RNA interference significantly inhibited growth of esophageal tumor cells. In addition, EB1 overexpression induced nuclear accumulation of b-catenin and promoted the transcriptional activity of b-catenin/T-cell factor (TCF). These effects were partially or completely abolished by coexpression of APC or DN TCF4, respectively. Also, we found that EB1 affected the interaction between b-catenin and APC. Furthermore, EB1 overexpression was correlated with cytoplasmic/ nuclear accumulation of b-catenin in primary human ESCC. Taken together, these results support the novel hypothesis that EB1 overexpression may play a role in the development of ESCC by affecting APC function and activating the b-catenin/TCF pathway. Oncogene (2005) 24, 6637-6645.
Introduction
Esophageal cancer (EC) is prevalent in specific regions of the world, and occurs at a very high frequency in certain parts of China (Parkin et al., 1999; Zou et al., 2002) . The major EC type in China is esophageal squamous cell carcinoma (ESCC). Squamous cell carcinoma of the human esophagus has a multifactorial etiology that includes environmental as well as genetic factors (Stoner and Gupta, 2001) . Despite advances in detection and treatment, the mortality of ESCC remains high (Parkin et al., 1999) . In China, the EC mortality rate is ranked fourth among cancer-related deaths (Zou et al., 2002) . Therefore, a better understanding of the molecular mechanisms that contribute to ESCC progression will facilitate the development of more effective diagnostic and treatment modalities for this cancer.
A previous study using cDNA expression arrays led to the identification of End-binding protein 1 (EB1) as one of the 61 genes that were found upregulated in ESCC tissues out of 588 genes analysed (Zhou et al., 1999) . However, the molecular role of EB1 in the development of ESCC remains to be elucidated.
Human EB1 was originally cloned in a yeast twohybrid screen by its ability to interact with the carboxyl terminus of the adenomatous polyposis coli (APC) tumor suppressor (Su et al., 1995) . EB1 belongs to the microtubule-associated, RP/EB protein family. Previous studies indicate that EB1, which localizes to spindle and cytoplasmic microtubules (Berrueta et al., 1998) , may regulate microtubule dynamics, cell polarity and chromosome stability (Tirnauer and Bierer, 2000) . However, it is unknown whether EB1 has additional roles in regulating cell growth and how it contributes to tumor development.
Since EB1 interacts with APC, it may be hypothesized that EB1 is a component of the APC tumor suppressor pathway, which can regulate the protein levels of b-catenin by forming a complex with glycogen synthesis kinase 3b (GSK 3b) and Axin (Giles et al., 2003) . Under physiological conditions, formation of this complex results in the rapid degradation of b-catenin. Loss of APC function leads to nuclear accumulation of bcatenin, where it binds to T-cell factor/lymphoid enhancing factor (TCF/LEF) and activates the transcription of multiple target genes, including c-myc and cyclin D1 (He et al., 1998; Shtutman et al., 1999; Polakis, 2000) . We propose that overexpression of EB1 in human ESCC might affect APC tumor suppressor activity including its ability to mediate b-catenin degradation. As a result, the b-catenin/TCF pathway might be aberrantly activated resulting in the transcriptional upregulation of TCF/LEF target genes.
To test our hypothesis, the EB1 cDNA was cloned and transfected into human ESCC cells and the effects of EB1 overexpression on cellular growth and transcriptional activity of b-catenin/TCF were analysed. We report that elevated expression of EB1 can promote cellular growth, probably through activation of the b-catenin/TCF pathway. In addition, we show that EB1 is overexpressed in many human ESCC tissues.
Results

Elevated expression of EB1 in human ESCC
The expression of EB1 mRNA in human ESCC was determined by reverse transcription-polymerase chain reaction (RT-PCR) analysis. Specific EB1 primers yielded a 333-bp EB1 cDNA fragment and RT-PCR with detection primers for b-actin as an internal control yielded a 200-bp b-actin cDNA fragment (Figure 1a ). EB1 mRNA was detected in all 27 cases of ESCC that were analysed. Expression levels of EB1 mRNA were elevated in 17 cases of ESCC compared to corresponding surrounding noncancerous esophageal tissues (Table 1) . These results are consistent with an earlier report (Zhou et al., 1999) . In addition, multiple ESCC cell lines were examined for EB1 protein expression by Western blot analysis. The highest level of EB1 expression was detected in KYSE410 and KYSE510 cells (Figure 1b) . The finding that EB1 is overexpressed in human ESCC tissue samples and multiple ESCC cell lines suggests that EB1 may play a role in the development of this malignancy.
Role of EB1 in the growth of human ESCC cells
Next we evaluated the effects of EB1 on the growth of the ESCC cell line EC9706 and KYSE510. EB1 has been shown to regulate microtubule dynamics, cell polarity and chromosome stability (Tirnauer and Bierer, 2000) . It remains unclear, however, whether EB1 has additional roles in regulating cellular growth. To address this question, EC9706 cells were transfected with pcDNA3/ HA-EB1 or pcDNA3 and selected with G418 to obtain stable transfectants (Figure 2 ). The resulting pool of stable transfectants was designated 9706/EB1 and 9706/ control, and cell growth assays were performed. 9706/ EB1 and 9706/control cells were plated at equal densities and cells were counted every 2 days. These experiments showed that EB1 significantly promoted the growth of EC9706 cells, with a 30-120% elevation in the growth rate observed at different time points in three independent experiments (Figure 3a ). In addition, we observed that expression of APC or DN TCF4 in 9706/EB1 cells decreased the growth rate of these cells (Figure 3b ), whereas expression of APC or DN TCF4 had no growth Figure 4a ) and KYSE510 cells (Figure 4b ) compared to pSilencer-control-transfected cells. Suppression of EB1 expression markedly inhibited the growth rates of these cells, with a 35-60% decrease in 9706/EB1 cells and a 50-70% decrease in KYSE510 cells at different time points, consistently in three separate experiments (Figure 4c, d) . These results suggest that EB1 may play a role in mediating the growth advantage seen in ECs and that this effect might be exerted via affecting the function of the APC tumor suppressor thereby activating the b-catenin/TCF pathway.
EB1 activates b-catenin-dependent gene expression
To further test the model that EB1 regulates the b-catenin/TCF pathway, we investigated whether EB1 can affect the subcellular localization of b-catenin and its transcriptional activity. To address these issues, immunocytochemistry and reporter assays were performed. We found increased nuclear staining of b-catenin in 9706/EB1 cells compared to 9706/control cells ( Figure 5a ). In 9706/control cells, only approximately 6.7% cells showed nuclear staining of b-catenin; but in 9706/EB1 cells, the percentage of cells with b-catenin nuclear accumulation was approximately 23.7% (Figure 5b ). The uneven b-catenin staining may reflect the fact that 9706/EB1 cells represent a pool of many clones that may express EB1 at different levels. When b-catenin is present in the nucleus, it is able to bind in conjunction with TCF/LEF to elements found in the promoters of a variety of cellular genes (Willert et al., 2002) . Hence, we studied the effect of EB1 on the transcriptional activity of b-catenin/TCF. The luciferase reporters TOPFLASH and FOPFALSH, which have a minimal thymidine kinase (TK) promoter and either wild type (TOP) or mutated (FOP) binding sites for the b-catenin/TCF complex, have been widely used to characterize b-catenin/TCF-dependent gene expression (Ishitani et al., 1999) . These reporter constructs were transfected into HeLa cells, and luciferase activity was determined.
In HeLa cells, overexpression of EB1 increased TOPFLASH activity in a dose-dependent manner These results indicate that EB1 overexpression causes the nuclear accumulation of b-catenin and results in the activation the b-catenin/TCF-dependent gene expression.
EB1 can affect the interaction between APC and b-catenin
The EB1 protein has been shown to associate with APC in human cells (Su et al., 1995) . The APC tumor suppressor protein forms a complex with GSK 3b, Axin and b-catenin, which regulates the levels of b-catenin (Giles et al., 2003) . Hence, we hypothesized that the interaction between APC and EB1 may affect the association of APC with b-catenin. To test this hypothesis, HEK293 cells were transfected with pcDNA3/HA-EB1 or control vectors and subjected to immunoprecipitation (IP) with APC or b-catenin 
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Y Wang et al specific antibodies. As expected, b-catenin was detected in anti-APC immunoprecipitates and APC was detected in anti-b-catenin immunoprecipitates in control-vectortransfected cells, confirming the interaction in vivo between these two proteins ( Figure 7 ). In addition, EB1 was detected in anti-APC immunoprecipitates. However, less b-catenin was detected in anti-APC immunoprecipitates in cells overexpressing EB1 (Figure 7) . Similarly, less APC was immunoprecipitated by anti-b-catenin antibodies ( Figure 7 ). These results are consistent with our model that overexpression of EB1 can interfere with the interaction between b-catenin and APC. This may result in the inhition of the degradation process for b-catenin. As a consequence, there are increased levels of nuclear b-catenin and enhanced transcription of b-catenin/TCF responsive genes as we have observed in EB1 overexpression ESCC cells.
Correlation between subcellular localization of b-catenin and overexpression of EB1 in human ESCC tissues
To examine whether EB1 expression is correlated with increased expression and nuclear localization of b-catenin in primary EC tissues, we compared the expression of EB1 and the subcellular localization of b-catenin in 60 primary human ESCC tissues by immunohistochemical staining. As we reported previously, b-catenin has an aberrant expression pattern in ECs Zhang et al., 2005) . In total, 65% (39/60) of EC samples showed loss of b-catenin localization at membranes accompanied by cytoplasmic/ nuclear accumulation. More importantly, in most cases, b-catenin accumulation was correlated with high levels of EB1 expression in tumor specimens, whereas tumor tissues showing membrane localization of b-catenin generally contained relatively low levels of EB1 ( Figure 8 ; Table 2 ). In 60 ESCC tumor tissues examined, there was a significant correlation between EB1 and b-catenin expression, as determined by the Spearman rank correlation test (Po0.05). These results further confirm that EB1 can modulate the b-catenin/TCF pathway in EC.
Discussion
Human tumorigenesis is a multistep process, in which a succession of genetic changes, each conferring one or another type of growth advantage, leads to progressive conversion of normal human cells into cancer cells Immunoprecipitates were subjected to SDS-PAGE followed by immunoblot analysis with the indicated antibodies. Equal amounts of cellular protein extracts were subjected for each IP reaction. Experiments were repeated three times with similar results Hanahan and Weinberg, 2000) . Previous studies suggested that six or seven mutations may be minimally necessary for the development of EC (Uys and van Helden, 2003) . The development of high-throughput techniques, such as cDNA expression arrays, permits the rapid and simultaneous examination of the expression levels of tens of thousands of genes (Schena et al., 1995) . EB1 was identified several years ago by cDNA expression array analysis as a gene that is frequently upregulated in human ESCC (Zhou et al., 1999) , but its role in the development of this malignancy remains unknown. In our present study, we confirmed overexpression of EB1 in ESCC. Expression of EB1 mRNA was elevated in 63% (17/27 cases) of ESCC compared to adjacent normal mucosa. The human EB1 gene maps to chromosome 20q11.1-11.23 (Su et al., 1995) and previous studies using comparative genomic hybridization (CGH) demonstrated that 20q amplification is one of the most common genomic aberrations in human ESCC (Yen et al., 2001; Struski et al., 2002) . Hence, gene amplification at chromosome 20q may contribute to EB1 overexpression in ESCC.
Overexpression of EB1 in human ESCC
EB1 is an evolutionarily conserved protein that is expressed in nearly every cell type examined, including neural, lymphocytic and epithelial cells (Tirnauer and Bierer, 2000) . It was initially identified by its physical association with the carboxyl terminal portion of the APC tumor suppressor protein (Su et al., 1995) . APC has a broad spectrum of functions, ranging from control of the Wnt signal pathway, to regulation of cell adhesion, migration and apoptosis, as well as chromosomal segregation during mitosis (Fodde et al., 2001) . The interaction of EB1 with APC is important for APC to associate with microtubule and cytoskeleton structures and to mediate chromosome segregation. It has been demonstrated that EB1 may target APC to the ends of microtubules, facilitating delivery or interaction of APC with specific sites at the cell membrane (Tirnauer and Bierer, 2000) . APC also plays a complex role in the Wnt pathway, which is important in regulating cellular growth, differentiation and morphogenesis (Polakis, 2000) . APC, in association with The level of EB1 expression and localization of b-catenin were determined in 60 surgical specimens of ESCC, as shown in Figure 8 . The correlation was analysed using a Spearman rank correlation test Po0.05
Overexpression of EB1 in human ESCC Y Wang et al GSK-3b, axin/conductin, forms a destruction complex, which binds and phosphorylates free b-catenin in the cytoplasm. This targets b-catenin for ubiquitylation and for subsequent proteosomal degradation. Moreover, APC, which harbors nuclear localization signals (NLS) as well as nuclear export signals (NES), was involved in mediating nuclear transport of b-catenin. Loss of function of APC, mostly as a result of mutations, induces the aberrant nuclear accumulation of b-catenin. Upon entering the nuclear compartment, b-catenin binds to TCF/LEF and activates the transcription of target genes, including c-myc and cyclin D1 (He et al., 1998; Shtutman et al., 1999) . Here, we demonstrate that EB1 can promote cellular growth and that this is mediated at least in part through activation of the b-catenin/TCF pathway. Ectopic EB1 expression in EC9706 cells results in increased cell growth. This effect can be reversed by coexpression of APC or DN TCF4 demonstrating that the growth promoting effect of EB1 overexpression is mediated by the APC-b-catenin/TCF pathway. Conversely, RNAi mediated depletion of EB1 inhibits the growth rate of 9706/EB1 and KYSE510 cells. Overexpression of EB1 in EC9706 cells also induces the nuclear accumulation of b-catenin and causes increased expression of b-catenin/ TCF target genes, including c-myc and cyclin D1 in the ESCC cell line EC9706. Meanwhile, EB1 can promote the transcriptional activity of b-catenin/TCF in HeLa cells and coexpression of APC or DN TCF4 can completely abolish these effects. We demonstrate that EB1 can interfere with b-catenin and APC association. The significance of these observations is further illustrated by our findings that upregulation of EB1 in a panel of primary ESCC specimens is significantly correlated with aberrant b-catenin expression and localization.
Our study suggests that EB1 may interact with the APC tumor suppressor protein and affect the formation of the destruction complex for b-catenin formed by APC, GSK-3b, axin/conductin, resulting in subsequent aberrant nuclear accumulation of b-catenin and elevated transcriptional activity of b-catenin/TCF. The transcription of several downstream targets of b-catenin/TCF pathway, such as c-myc and cyclin D1, are activated and contributed to the enhanced cellular growth. To our knowledge, this is the first study that establishes a role of EB1 in the development of ESCC and in regulating the b-catenin/TCF pathway.
In summary, EB1 is overexpressed in human ESCC and promotes cellular growth. In addition, our study also indicates that EB1 may regulate cellular growth via the APC-b-catenin/TCF pathway.
Materials and methods
Tissue samples
We analysed tissues from excised ESCC of patients treated at Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. Two tissue samples were taken from each patient: one from the tumor and one from the resection margin. Tissue samples were immediately frozen at À801C until analysis, while the remaining tissues were used for histological classification by the local pathology department. All tumors were verified as squamous cell carcinoma with various degrees of differentiation. The tissues from the resection margins likewise were examined histologically and all were found to be free of tumor cells.
RNA extraction and RT-PCR
While still frozen, the tissues were minced thoroughly. Total RNA was extracted from esophageal specimens by using TRIZOL Reagent (Invitrogen) according to the standard protocol. The integrity of the RNA samples was determined by electrophoresis through agarose gels and staining with ethidium bromide, and the 18S and 28S RNA bands were visualized under UV light. Total RNA (5 mg) was used for cDNA synthesis by reverse transcription using mouse-mammary tumor virus (M-MLV) Reverse Transcriptase (Promega), according to the manufacturer's protocol in a total volume of 25 ml. All PCR reactions were performed using standard PCR conditions: 951C 5 min, 951C 1 min, annealing 541C 1 min, extension 721C 1 min for 30 cycles, and a final extension at 721C for 10 min. The PCR products were visualized by electrophoresis in 2% agarose gels, followed by staining with ethidium bromide, and quantified using a Gel EDAS 290 analysis system (Cold Spring USA Corporation) and Gel-Pro Analyzer 3.1 software (Media Cybernetics). The primer pair used for amplification of the human EB1 was: forward primer, 5 0 -CTGCGTATTGTCAGTTTATG-3 0 , and reverse primer, 5 0 -GAGGTTTCTTCGGTTTATTC-3 0 . As an internal standard, a fragment of human b-actin was co-amplified by PCR using the following primers: forward primer, 5 0 -GGCGG CACCACCATGTACCCT-3 0 , and reverse primer, 5 0 -AGG GGCCGGACTCGTCATACT-3 0 .
Plasmid constructions, cell culture, and transfection
To generate the EB1 expression vector, the open reading frame of the human EB1 cDNA was cloned into the eukaryotic expression vector pcDNA3 (Invitrogen) and was fused to an amino-terminal hemagglutinin (HA) tag. The resulting plasmid was designated pcDNA3/HA-EB1. The EB1 knockdown vector (pSilencer-EB1) and the control RNAi vector (pSilencer -control) were constructed as described previously . The EB1 RNAi was targeted against the human EB1 sequence: 5 0 -TTGCCTTGAAGAAAGTGAA-3 0 (Louie et al., 2004) ; while the control RNAi was targeted against the sequence: 5 0 -GACTCTTCCAGTGGTTTAA-3 0 , which is with limited homology to any known sequences in the human genome. The APC expression plasmid was a kind gift from Professor B Vogelstein (John Hopkins University, Baltimore, MD, USA). The construct expressing a dominant-negative mutant of TCF4, commonly referred to as DN TCF4, was a kind gift from Professor ER Fearon (University of Michigan School of Medicine, Ann Arbor, MI, USA). TOPFLASH, FOPFLASH were purchased from Upstate and pRL-TK was purchased from Promega.
The human ESCC cell line, EC9706, was kindly provided by Professor MR Wang (Peking Union Medical College, Beijing, China). HEK293 and HeLa cells were obtained from the American Type Culture Collection (Manassas, VA, USA). EC9706 cells were grown in Medium 199 (Invitrogen). HEK293 and HeLa cells were grown in DMEM (Invitrogen). Other ESCC cell lines (KYSE150, KYSE410, and KYSE510 cells) were grown in RPMI 1640 medium (Invitrogen). All media were supplemented with 10% fetal bovine serum (Gibco BRL), 50 U/ml penicillin and 50 mg/ml streptomycin. These cells were maintained in a humidified 371C incubator with 5% CO 2 , fed every 3 days with complete medium, and subcultured when confluence was reached.
Transfections were performed in six-or 24-well plates. A total of 2 Â 10 5 cells were seeded into each well of a six-well tissue culture plate (Costar). The next day when the cells were 70-80% confluent the culture medium was aspirated, and the cell monolayer was washed with prewarmed sterile phosphate-buffered saline (PBS). Cells were transfected with the appropriate plasmids using LipofectAMINEt 2000 Reagent (Invitrogen), according to the manufacturer's protocol. The cells were harvested at different time points. Western blot analysis or other experiments were performed. For the establishment of stable transfectants of pcDNA3/HA-EB1 or pcDNA3, after transfection, cells were selected with G418, and resistant clones were pooled and cultured. HA-EB1 expression was confirmed by Western blot. The resulting resistant clones populations were designated 9706/EB1 and 9706/control.
IP and Western blot analyses
For IP, HEK293 cells were harvested at 36 h after transfection and lysed with Nonidet P40 lysis buffer (10 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.5% NP-40, 0.5 mg/ml leupeptin, 1.0 mg/ml pepstatin, 0.2 mM PMSF). Cell lysates were precleared by incubation for 1 h with Protein G-Sepharose (Amersham Biosciences)/mouse IgG complexes. The supernatant fraction was recovered and immunoprecipitated with 1 mg anti-APC antibody (Ab-5; Oncogene Research) or anti-b-catenin antibody (C19220; BD Transduction Laboratories) and 10 ml Protein G-Sepharose. After being washed three times with lysis buffer, pellets were resuspended in 2 Â Laemmli sample buffer and then analysed by SDS-PAGE and Western blot as described below.
Cells were harvested at different time points and lysed in lysis buffer, then Western blot analysis was performed with the use of conventional protocols as described previously . In brief, total proteins or IP samples were separated by SDS-PAGE, then transferred onto nitrocellulose membranes (PROTRAN). The antibodies and dilutions used included anti-APC (Ab-1; 1 : 100; Oncogene Research), anti-bactin (AC-15; 1 : 5000; Sigma), anti-b-catenin (C19220; 1 : 5000; BD Transduction Laboratories), anti-c-Myc (9E10; 1 : 1000; Santa Cruz), anti-cyclin D1 (DCS-6; 1 : 1000; DAKO), anti-EB1 (Clone 5; 1 : 1000; BD Transduction Laboratories), anti-HA (Y11; 1 : 1000; Santa Cruz), and after extensive washing the membranes were incubated with anti-mouse IgG-horseradish peroxidase conjugate antibody (Zhongshan Company) for 1 h at room temperature and developed with a Luminol chemiluminescence detection kit (Santa Cruz). Membranes were reprobed for b-actin to normalize for loading and to allow for accurate quantification. Protein expression was quantified using a Gel EDAS 293 analysis system (Cold Spring USA Corporation) and Gel-Pro Analyzer 3.1 software (Media Cybernetics).
Cell growth assay
Cells transfected with indicated plasmids were harvested and replated at a density of 50 cells/mm 2 in triplicate. The total cell number was determined every 2 days by using a hematocytometer and an Olympus inverted microscope. Cell viability was assessed by using trypan blue exclusion.
Immunocytochemisty and immunohistochemistry
For immunocytochemistry, 9706/control and 9706/EB1 cells were grown on coverslips. The next day, cells were fixed with ice-cool methanol-acetone and permeabilized with 0.2% Triton X-100. Immunocytochemistry was performed using an UltraSensitivet Kit (Maixin-Bio), according to the manufacturer's protocol. In brief, after endogenous peroxidase activity was quenched, cells were blocked with normal nonimmune serum. The excess serum was removed and cells were incubated for 60 min with anti-b-catenin (C19220; Transduction Lab) diluted at 1 : 100. Each incubation step was carried out at room temperature and was followed by three sequential washes (5 min each) in PBS. Cells were then incubated with biotinconjugated secondary antibody for 30 min, followed by incubation with streptavidin-peroxidase for 30 min. Peroxidase activity was identified by applying 3,3 0 -diaminobenzidine tetrachloride. Cells were rinsed in water and counterstained with hematoxylin. Finally, cells were dehydrated in alcohol, cleared in xylene. The cells with nuclear accumulation of bcatenin were counted under a microscope. Six fields each containing with >400 cells in each were randomly counted for each sample.
Immunohistochemistry was performed as described previously Zhang et al., 2005) . The antibodies and dilutions used included anti-b-catenin (C19220; 1 : 50; BD Transduction Laboratories) or anti-EB1 (Clone 5; 1 : 50; BD Transduction Laboratories). Slides were treated with anti-b-catenin antibody or anti-EB1 antibody at 41C in a humidified chamber for 12 h. All immunostaining experiments were assessed by an experienced pathologist, who was and the samples were blinded. EB1 protein expression within the cancer tissue was evaluated and categorized according to the percentage of cancer cells immunostained (1p10%; 2 ¼ 11-25%; 3 ¼ 26-50%; 4X51%). Tumors were then further grouped into low (score 1) and high (score 2-4) expression of EB1. b-Catenin protein expression profiles in cancer tissues were grouped into cytoplasm/nuclear expression and membrane expression only Zhang et al., 2005) .
Reporter assay
To determine the effects of EB1 on b-catenin/TCF reporter constructs, cells were replated and transfected in 24-well plates, with either TOPFLASH or FOPFLASH (100 ng) and the internal control plasmid pRL-TK (5 ng) (Promega) and other plasmids indicated, using LipofectAMINEt 2000 Reagent (Invitrogen). The TOPFLASH and FOPFLASH reporters contain two sets of three copies of wild type or mutant b-catenin/TCF binding sites, respectively, as well as the TK minimal promoter upstream of the Firefly Luciferase open reading frame. The cells were incubated for 36 h at 371C, washed with PBS, and then lysed to measure luciferase reporter gene expression by dual-luciferase reporter assay system (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity. All results are expressed as means7s.d. for independent triplicate cultures.
Statistical analysis
SPSS for Windows (SPSS Inc.) was used for statistical analysis. Correlation between the EB1 expression levels and b-catenin expression profiles on a per case basis was further analysed by Spearman's rho correlation coefficient test. Values of Po0.05 were considered statistically significant.
